RNS Number: 1666 Z Nuformix PLC 15 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1654 Z Nuformix PLC 15 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Triggers Additional £500 k Payment for NXP001. Cambridge, UK, 15 May 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that in accordance with its updated agreement with Newsummit Biopharma, its licensing partner for China as announced on 27...
RNS Number: 6586 Y Nuformix PLC 10 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3386 Y Nuformix PLC 08 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Andrew Hore Quoted Micro 15 April 2019 NEX: #HASH #ESO #ANGP #LUCE #NQMI AIM: #SUMO #DEST #ANX #RAI #SAF #IQG #LWRF #GOR #SML #PSL #ROSE #CPT LSE: #NANO #BON #CGO #TOOP #NFX #ZEG #WDC
RNS Number: 6726 V Nuformix PLC 09 April 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6715 V Nuformix PLC 09 April 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge, UK, 9th April 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, today announces it has signed an agreement for cannabinoid therapeutics development, licensing and commercialisation containing up to £51 million of upfront, R&D and milestone...
Nuformix plc
NFX.L
Nuformix plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    460.75M

Featured Media

Company Profile

Nuformix is a pharmaceutical development company using cocrystal technology, unlocking the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.

Classification

Market Indices-

Locations

HQ
153 Cambridge Science Park
Milton Road
CB4 0GH
Cambridge
Watchlist